Ionis Pharmaceuticals | Sustainability Performance
Engages in the research and development of RNA-targeted therapeutics. Its pipeline addresses rare diseases, neurological conditions, and cardiovascular disorders. The company applies antisense technology to create treatments that regulate protein production, with several programs advancing through clinical trials.
1989
United States
1,001 - 5,000 employees
Biotechnology
$500M - 1B in revenue
Not profitable
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#8579
Overallⓘ#1980
in United Statesⓘ#201
in BiotechnologyⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Financial Data
Business performanceCapital & innovationAnalyst projections
Controversy level
Powered by illuminem
Sustainability employees
ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.Total sustainability employees
4-6
ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.